Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Cytek Biosciences (CTKB) Receivables - Net (2020 - 2025)

Cytek Biosciences' Receivables - Net history spans 6 years, with the latest figure at $62.5 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 3.17% year-over-year to $62.5 million; the TTM value through Dec 2025 reached $62.5 million, up 3.17%, while the annual FY2025 figure was $62.5 million, 3.17% up from the prior year.
  • Receivables - Net reached $62.5 million in Q4 2025 per CTKB's latest filing, up from $56.6 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $62.5 million in Q4 2025 to a low of $24.0 million in Q2 2021.
  • Average Receivables - Net over 5 years is $46.4 million, with a median of $49.6 million recorded in 2023.
  • Peak YoY movement for Receivables - Net: skyrocketed 75.16% in 2021, then decreased 10.04% in 2024.
  • A 5-year view of Receivables - Net shows it stood at $29.8 million in 2021, then surged by 64.19% to $48.9 million in 2022, then grew by 14.46% to $55.9 million in 2023, then rose by 8.33% to $60.6 million in 2024, then grew by 3.17% to $62.5 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Receivables - Net are $62.5 million (Q4 2025), $56.6 million (Q3 2025), and $56.2 million (Q2 2025).